| DC21397 |
AI-1 |
Nrf2 acticatior AI-1 is a small-molecule inducer of the antioxidant response element (ARE) that activates and stabilizes Nrf2 by covalently modifying Keap1, activates an ARE-dependent luciferase reporter with an EC50 of 2.7 uM. |
|
| DC21398 |
AI-2 |
Nrf2 acticatior AI-2 is a small-molecule inducer of the antioxidant response element (ARE) that activates and stabilizes Nrf2 by covalently modifying Keap1. |
|
| DC20477 |
Nrf2 activator 16 |
Nrf2 activator 16 is a potent Keap1-Nrf2 and Keap1-p-p62 protein-protein interaction inhibitor with IC50 of 0.91 uM and 1.8 uM respectively. |
|
| DC21399 |
AEM1
Featured
|
NRF2 inhibitor AEM1 is a specific small molecule inhibitor of Nrf2 transcriptional activity in cancer cells, shows no activity against a panel of >100 kinases (including isoforms of PI3K, AKT, and PKC). |
|
| DC20251 |
NRX-103094
Featured
|
NRX-103094 is a potent enhancer of the interaction between β-catenin and its cognate E3 ligase, SCFβ-TrCP. It significantly strengthens the binding of the pSer33/Ser37 β-catenin peptide to β-TrCP, exhibiting an EC50 of 62 nM and a Kd of 0.6 nM. |
|
| DC20254 |
NRX-103095
Featured
|
NRX-103095 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20248 |
NRX-1532
Featured
|
NRX-1532 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20249 |
NRX-1933
Featured
|
NRX-1933 is an enhancer of an E3 ligase-substrate interaction. |
|
| DC20252 |
NRX-252114
Featured
|
NRX-252114 is a potent enhancer of the interaction between β-catenin and its cognate E3 ligase, SCFβ-TrCP. It significantly strengthens the binding of the pSer33/S37A β-catenin peptide to β-TrCP, exhibiting an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 also induces the degradation of mutant β-catenin. |
|
| DC20253 |
NRX-252262
Featured
|
NRX-252262 is a powerful enhancer of the interaction between β-Catenin and its cognate E3 ligase, SCFβ-TrCP. It effectively induces the degradation of mutant β-catenin, demonstrating an EC50 of 3.8 nM. |
|
| DC20250 |
NRX2663
Featured
|
NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 µM and a Kd of 54.8 nM[1]. |
|
| DC8789 |
NS 11021
Featured
|
NS 11021 is an activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1). |
|
| DC7787 |
NS-2028 |
NS 2028 is a specific inhibitor of soluble guanylyl cyclase. |
|
| DC8783 |
NS 9283
Featured
|
NS 9283 is a positive allosteric modulator of α4β2 receptor; increases the potency of Ach-evoked currents ~60 fold without effecting the maximum efficacy (HEK293-hα4β2 cells). |
|
| DC23137 |
NS-018 |
NS-018 (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM). |
|
| DC23130 |
NS-018 hydrochloride |
NS-018 hydrochloride (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM). |
|
| DC23131 |
NS-018 maleate
Featured
|
NS-018 maleate (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM). |
|
| DC22181 |
NS-062 |
NS-062 (NS062) is a novel, specific targeted covalent inhibitor that shows high reactivity toward Cys797 of EGFR. |
|
| DC8083 |
NS11394
Featured
|
NS11394 possesses a functional efficacy selectivity profile of alpha(5) > alpha(3) > alpha(2) > alpha(1) at GABA(A) alpha subunit-containing receptors. |
|
| DC9734 |
NS-1619
Featured
|
NS-1619 is a selective MaxiKα (large conductance calcium activated potassium channel) activator. |
|
| DC6910 |
NS-1643
Featured
|
NS1643 is a potent human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 μM). |
|
| DC8183 |
Paritaprevir(Veruprevir ABT-450)
Featured
|
NS3/4A protease inhibitor |
|
| DC20479 |
NS-3-008 hydrochloride |
NS-3-008 hydrochloride is a novel small-molecule transcriptional inhibitor of G0s2 (G0/G1 switch 2) with IC50 of 2.25 uM. |
|
| DC20478 |
NS-3-008 HCl
Featured
|
NS-3-008 is a novel small-molecule transcriptional inhibitor of G0s2 (G0/G1 switch 2) with IC50 of 2.25 uM. |
|
| DC9608 |
NS-304(Selexipag)
Featured
|
NS-304(Selexipag; ACT-293987) is an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
|
|
| DC7833 |
NS309
Featured
|
NS309 is a positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels. |
|
| DC8806 |
NS-398
Featured
|
NS-398 is a selective inhibitor of cyclooxygenase-2 (COX-2). |
|
| DC8269 |
NS6180
Featured
|
NS6180 is a novel inhibitor of the intermediate-conductance Ca2+-activated K+ channel (KCa3.1) |
|
| DC9856 |
NS638
Featured
|
NS638 is a Ca(2+)-channel blocker. |
|
| DC23798 |
NSC 145366 |
NSC 145366 is a novel, allosteric Hsp90 CTD (C-terminal domain) inhibitor, exhibits anti-proliferative activity in tumor cell lines with GI50 of 0.2-1.9 uM. |
|
